OCREVUS Market Summary
Key Factors Driving OCREVUS Growth
1. Large and Unmet Patient Population in MS
OCREVUS treats both relapsing and progressive forms of MS — a chronic neurological disease affecting millions worldwide. MS broadly drives demand because:
• It provides one of the few approved options for PPMS, a progressive form of MS with limited treatments.
• Many patients with RMS seeking high-efficacy therapies opt for CD20-targeted treatments.
This broad disease coverage expands the addressable patient base compared with therapies that only treat one MS subtype.
2. Strong Clinical Profile Backed by Long-Term Data
Roche has consistently highlighted OCREVUS’s clinical benefits in slowing disease progression:
Long-term follow-up demonstrates reduced disability progression with continuous treatment in both relapsing MS and PPMS.
These data strengthen confidence among neurologists and support sustained prescription growth.
3. Subcutaneous (SC) Approval Improving Accessibility
Roche received regulatory approval for a subcutaneous 10-minute injection version of OCREVUS (branded, in some markets, as OCREVUS Zunovo) that:
Is administered twice yearly
• Offers a 10-minute injection alternative to traditional IV infusion
• This SC formulation was approved by the US FDA and European regulators and expected to broaden usage in clinics without infusion infrastructure, enhancing convenience.
This expanded route of administration helps OCREVUS remain competitive with monthly self-injectable MS therapies.
4. Continued Uptake and Global Sales Contribution
OCREVUS remains one of Roche’s top pharmaceutical growth assets:
• In 2024, OCREVUS generated CHF ~6.7 billion (~US$7.6 billion) in global sales — a 9 % increase year-over-year.
• In 2025 overall results, OCREVUS remains among Roche’s top five growth drivers (alongside Phesgo, Xolair, Hemlibra, Vabysmo), contributing meaningfully to the company’s pharmaceuticals revenue.
OCREVUS’s inclusion consistently in Roche’s top growth listings underscores its continued commercial momentum.
5. Market Dynamics — Strong Demand Despite Biosimilar Pressure in Other Areas
Roche’s overall pharmaceutical sales performance in recent reporting periods shows:
Pharma division up ~9 % (constant exchange rates) in 2025, with OCREVUS a key contributor among severe disease medicines.
This growth more than offset declines in other legacy products that lost exclusivity.
OCREVUS’s resilience helps Roche offset some portfolio losses and supports long-term revenue growth.
OCREVUS Recent Developments
• In February 2026, In real-world clinical practice, OCREVUS (ocrelizumab) showed sustained effectiveness in people with relapsing forms of multiple sclerosis (MS), with most patients remaining free from long-term worsening of disability over four years, according to a new study. Relapse rates and MRI disease activity were also low during follow-up. At four years, 39.7% of patients with available MRI data achieved no evidence of disease activity, defined as no relapses, no new MRI activity, and no confirmed worsening of disability.
• In September 2025, Roche presented new data for OCREVUS (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
“OCREVUS Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OCREVUS for approved indication like Multiple sclerosis in the 7MM. A detailed picture of OCREVUS’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OCREVUS for approved indications. The OCREVUS market report provides insights about OCREVUS’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OCREVUS performance, future market assessments inclusive of the OCREVUS market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OCREVUS sales forecasts, along with factors driving its market.
OCREVUS Drug Summary
OCREVUS (ocrelizumab) is a humanized monoclonal antibody targeting CD20-positive B cells, approved by the FDA for treating relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, as well as primary progressive MS (PPMS). Administered via intravenous infusion every six months (initial two doses two weeks apart at 600 mg each, then 600 mg maintenance), or as a subcutaneous injection option (OCREVUS ZUNOVO with hyaluronidase), it depletes pre-B and mature B lymphocytes through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis, thereby reducing antigen presentation to T cells, autoantibody production, pro-inflammatory cytokine release, and immune cell infiltration into the CNS. Pivotal Phase III trials (OPERA I/II for RMS, ORATORIO for PPMS) demonstrated significant reductions in annualized relapse rates (46-47%), new/enlarging T2 and gadolinium-enhancing lesions, and disability progression, with a sustained effect on MRI activity and neurofilament light chain levels. Common side effects include infusion reactions (up to 40%, mostly mild), infections (e.g., upper respiratory), and increased malignancy risk (e.g., breast cancer), necessitating HBV screening and PML monitoring. The report provides OCREVUS’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the OCREVUS Market Report
The report provides insights into:
• A comprehensive product overview including the OCREVUS MoA, description, dosage and administration, research and development activities in approved indication like Multiple sclerosis.
• Elaborated details on OCREVUS regulatory milestones and other development activities have been provided in OCREVUS market report.
• The report also highlights OCREVUS‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The OCREVUS market report also covers the patents information, generic entry and impact on cost cut.
• The OCREVUS market report contains current and forecasted OCREVUS sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OCREVUS market report also features the SWOT analysis with analyst views for OCREVUS in approved indications.
Methodology
The OCREVUS market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OCREVUS Analytical Perspective by DelveInsight
• In-depth OCREVUS Market Assessment
This OCREVUS sales market forecast report provides a detailed market assessment of OCREVUS for approved indication like Multiple sclerosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OCREVUS sales data uptil 2034.
• OCREVUS Clinical Assessment
The OCREVUS market report provides the clinical trials information of OCREVUS for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
OCREVUS Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
OCREVUS Market Potential & Revenue Forecast
• Projected market size for the OCREVUS and its key indications
• Estimated OCREVUS sales potential (OCREVUS peak sales forecasts)
• OCREVUS Pricing strategies and reimbursement landscape
OCREVUS Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• OCREVUS Market positioning compared to existing treatments
• OCREVUS Strengths & weaknesses relative to competitors
OCREVUS Regulatory & Commercial Milestones
• OCREVUS Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
OCREVUS Clinical Differentiation
• OCREVUS Efficacy & safety advantages over existing drugs
• OCREVUS Unique selling points
OCREVUS Market Report Highlights
• In the coming years, the OCREVUS market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OCREVUS companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OCREVUS’s dominance.
• Other emerging products for Multiple sclerosis are expected to give tough market competition to OCREVUS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OCREVUS in approved indications.
• Analyse OCREVUS cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OCREVUS sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OCREVUS in approved indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of OCREVUS? How strong is OCREVUS’s clinical and commercial performance?
• What is OCREVUS’s clinical trial status in each individual indications such as Multiple sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OCREVUS Manufacturers?
• What are the key designations that have been granted to OCREVUS for approved indications? How are they going to impact OCREVUS’s penetration in various geographies?
• What is the current and forecasted OCREVUS market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OCREVUS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OCREVUS for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is OCREVUS? What is the duration of therapy and what are the geographical variations in cost per patient?
